The implantable cardioverter-defibrillator. Current indications and controversies.
The implantable cardioverter-defibrillator (ICD) has become a highly effective, but expensive therapy for sudden cardiac death due to ventricular tachyarrhythmias. ICD use has been increasing at 20-30% per year, and is expected to rise at a faster rate. Clinical trials have now shown that the ICD can be effective for the secondary prevention, and more recently for the primary prevention, of sudden cardiac death in selected populations. Despite the high quality trial evidence that is currently available, several issues pertaining to ICD use remain unresolved. These relate to the management of patient groups who were not included in the clinical trials, optimizing the selection of patients who will benefit from an ICD, determining the duration of survival benefit from an ICD, assessing and optimizing a patient's quality of life with an ICD, and determining the cost-effectiveness and cost-impact of the ICD. These considerations are discussed in this article.
Raj
S R
SR
Cardiovascular Research Group, University of Calgary, Calgary, Alberta, Canada.
Sheldon
R S
RS
D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D006801:Humans; D017180:Tachycardia, Ventricular / Q000628:therapy*